Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer

International Journal of Gynecological Cancer

Volumn 13, Issue SUPPL. 2, 2003, Pages 144-148

  Piccart, Martin J ^a,f   Bertelsen, K ^b   Stuart, G ^c   Cassidy, J ^d   Mangioni, C ^a   Simonsen, E ^b   James, K ^c   Kaye, S ^d   Vergote, I ^a   Blom, R ^b   Grimshaw, R ^c   Atkinson, R ^d   Swenerton, K ^c   Trope, C ^b   Nardi, M ^a   Kaern, J ^b   Tumolo, S ^a   Timmers, P ^a   Roy, J A ^a   Lhoas, F ^a   Lidvall, B ^b   Bacon, M ^c   Birt, A ^d   Andersen, J ^b   Zee, B ^c   Paul, J ^d   Pecorelli, S ^a   Baron, B ^a   McGuire, W ^e   more..

^a EORTC DATA CENTER   (Belgium)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c QUEEN S UNIVERSITY   (Canada)

^d BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^e Division of Gynecologic Oncology   (United States)

^f JULES BORDET INSTITUTE   (Belgium)

Author keywords

Advanced stage; Chemotherapy; Cisplatin; Ovarian neoplasm; Paclitaxel

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MEDICAL SOCIETY; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANADA; CISPLATIN; CYCLOPHOSPHAMIDE; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 10744219986     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2003.13357.x     Document Type: Conference Paper

References (11)

1. McGuire WP, Hoskins WJ, Brady MF et al. A phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/taxol (PT) in advanced ovarian cancer (AOC). Proceeding of ASCO. American Society of Clinical Oncology Meeting, Orlando, 1993;12 [Abstract 808].
2. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
3. van der Burg ME, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629-34.
4. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamidein women with advanced epithelial ovarian cancer: three-year results. "Cisplatin-paclitaxel treatment for advance ovarian cancer resulted in longer survival than cisplatin-cyclophosphamide". J Natl Cancer Inst 2000;92:699-708.
5. du Bois A, Neijt JP, Thigpen JT. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - A new standard of care? Ann Oncol 1999;10:35-41.
6. Neymark N, Gorlia T, Adriaenssen L Baron B, Piccart M. Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium. Pharmacoeconomics 2002;20:485-97.
7. Muggia F, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000;18:106-15.
8. Advanced Ovarian Cancer Trialist Group. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Br J Cancer 1998;78:1479-87.
9. The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505-15.
10. The ICON Collaboration. ICON2: randomised trial single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet 1998;352:1571-6.
11. Sandercock J, Parmar MKB, Torri V, Qian W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer 2002;87:815-24.